Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1895 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
 


 

 
     
    Advanced search
 

 
 
     
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed1264    
    Printed48    
    Emailed0    
    PDF Downloaded199    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO EDITOR Table of Contents   
Year : 2009  |  Volume : 51  |  Issue : 3  |  Page : 228
Use of milnacipran in patients suffering from poststroke depression


Department of Psychiatry, GGS Medical College, Faridkot, Punjab-151203, India

Click here for correspondence address and email

Date of Web Publication8-Sep-2009
 

How to cite this article:
Arora H, Kaur R. Use of milnacipran in patients suffering from poststroke depression. Indian J Psychiatry 2009;51:228

How to cite this URL:
Arora H, Kaur R. Use of milnacipran in patients suffering from poststroke depression. Indian J Psychiatry [serial online] 2009 [cited 2019 Nov 18];51:228. Available from: http://www.indianjpsychiatry.org/text.asp?2009/51/3/228/55099


Sir,

It is known that depression is common after stroke. According to a recent report using DSM- IV [1] criteria, the prevalence of major or minor depression among hospitalized patients following a stroke is 22% and 17% respectively. [2]

The etiological relationship between stroke and depression has been investigated in recent years and a biological basis of many cases of post stroke depression has been suggested. [3],[4],[5] Patients with post stroke depression are generally less willing to participate in rehabilitation programs and the recovery of activities of daily living is often delayed.

Stroke patients tend to be older and frailer than normal depressed patients and are particularly sensitive to the side effects of the tricyclic antidepressants. The Serotonin-norepinephrine reuptake inhibitor (SNRI), milnacipran, has been reported to be as effective as conventional antidepressants. While having fewer drug interactions and side effects; [6] its use in the treatment of post stroke depression has been investigated in our study.

Fifteen patients with depression whose onset followed a cerebral infarction or hemorrhage (stroke) have been included in the study. All patients were diagnosis for major depressive disorder using DSM-IV criteria. The severity of depression was measured at baseline and after two, four and six weeks using the 21- item Hamilton rating scale for depression.

The patient group comprised of seven males and eight females, age ranged from 45-75 years (mean age 60.8 years). With regard to the type of stroke, nine patients experienced cerebral infarction and six suffered from cerebral hemorrhage. The lesion location was left hemisphere in seven patients, right hemisphere in five patients, and both hemispheres in three patients. Nine patients had motor deficit, five had sensory deficit, two had dysarthria and one had visual field deficit.

Initially, 50 mg /day of milnacipran was administered twice daily in the morning and at night, the dosage was adjusted weekly according to clinical symptoms. The maximum daily dose of milnacipran was in the range of 50-100 mg twice daily. Patients were allowed to take short acting hypnotics when necessary.

One patient dropped out. One complained of headache and yet another of nausea. No other side effect was noticed.

At the end of the study, 85.71% (12/14) of patients completing the study were in remission (a final Hamilton Rating Scale for Depression score of less than seven and no longer meeting the criteria of major depression).

Major improvements were seen in the main Hamilton Rating Scale for Depression items such as depressed mood, work efficiency, psychomotor retardation, psychic anxiety, somatic anxiety, general somatic symptoms, hypochondriasis.

This study demonstrates the efficacy of milnacipran in post stroke depression treatment. Even at a relative low dose of 50-100 mg/day, milnacipran alleviated the symptoms of depression after one/two weeks suggesting that milnacipran has a relatively fast onset of action in these types of patient. Milnacipran was generally well tolerated.

The present study was an open label study and hence it will be necessary to examine more cases and conduct double-blind studies using placebo or other antidepressants. The results from our study suggest that milnacipran may be a promising drug for the treatment of post stroke depression.

 
   References Top

1.Diagnostic and Statistical Manual of Mental Disorders, 4th edition. American psychiatric Association. Washington, DC: American Psychiatric Association Press; 1994.  Back to cited text no. 1    
2.Chemerinski E, Robinson RG. The neuropsychiatry of stroke. Psychosomatics 2000;41:5-14.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Robinson RG, Szetela B. Mood change following left hemispeheric brain injury. Ann Neurol J 1981;9:447-53.  Back to cited text no. 3    
4.Morris PL, Robinson RG, de Carvalho ML, Albert P, Wells JC, Samuels JF, et al . Lesion characteristics and depressed mood in stroke data bank study. J Neuropsychiatry Clin Neurosci 1996;8:153-9.  Back to cited text no. 4  [PUBMED]  
5.Astrom M, Adolfson R. Major depression in stroke patients: A three year longitudinal study. Stroke 1993;24:976-82.  Back to cited text no. 5    
6.Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108.  Back to cited text no. 6  [PUBMED]  

Top
Correspondence Address:
Harish Arora
Department of Psychiatry, GGS Medical College, Faridkot, Punjab-151203
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5545.55099

Rights and Permissions




 

Top